GRACE :: Lung Cancer

Met

Denise Brock

ASCO 2017 – Lung Cancer – Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss  Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?  



 

 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


ExecDirCarlea

Breakthroughs in Lung Cancer from 2014 from Thomas John, MD

Share

Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.

For those who wish to access the PDF, it’s here: Thomas John, MD Top Four Lung Cancer Highlights 2014

Agree? Disagree? What are you looking forward to in 2015?


GRACE Video

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

Share

“Dead negative,” is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

OAM4971g: Overall Survival Results


GRACE Video

MET-Amplified Lung Cancer: A New Target for XALKORI?

Share

Lung cancer patients with high MET amplification appear to do well on Xalkori (crizotinib), a drug that is approved for ALK positive patients.


GRACE Video

What’s the Status and Potential Utility of Cabozantinib in Lung Cancer?

Share

Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib – a drug already approved for thyroid cancer – can help patients with lung cancer. February 2014.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243